-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Ascendis Pharma, Lowers Price Target to $335

Benzinga·11/13/2026 12:35:16
Listen to the news
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and lowers the price target from $344 to $335.